Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 8/20 | 0.41 |
| ▸ | FABP3 | P05413 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5210888 | 0.77 | CRHR1 (0.48) | — | |
| SCHEMBL5206955 | 0.75 | CRHR1 (0.62) | — | |
| SCHEMBL4459937 | 0.70 | FABP3 (0.52) | DHODHFABP3FABP4DPP4CYP3A4 | |
| SCHEMBL9907383 | 0.69 | KDM4C (0.49) | DHODHKDM4C | |
| SCHEMBL8874315 | 0.69 | DHODH (0.56) | DHODHFABP3FABP4LMNADPP4 | |
| SCHEMBL6352059 | 0.67 | TSHR (0.51) | DHODHKDM4CCNR1CNR2 | |
| SCHEMBL20659681 | 0.66 | LMNA (0.54) | KDM4CLMNADPP4DPP8 | |
| SCHEMBL9907459 | 0.65 | KDM4C (0.45) | KDM4C | |
| SCHEMBL15491613 | 0.65 | FABP3 (0.62) | DHODHFABP3FABP4CYP2C9 | |
| SCHEMBL11373441 | 0.64 | SMURF2 (0.46) | LMNADPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6974808-B2 | CRF receptor antagonists and methods relating thereto | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| US-20020049207-A1 | CRF receptor antagonists and methods relating thereto | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-25 | — | — | US | disclosed |
| US-6352990-B1 | A METHOD OF TREATING ANXIETY AND DEPRESSION IN A WARM-BLOODED ANIMAL AND TREATMENT OF STROKES | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-05 | — | — | US | disclosed |
| EP-0970082-A2 | BIAZACYCLIC CRF ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998035967-A2 | BIAZACYCLIC CRF ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049207-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRH, CRHR2 | DHODH 1541/4885FABP3 411/4885FABP4 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.